Strand Therapeutics Inc. is a Boston-based biotech company that is revolutionizing the field of mRNA therapeutics. With their proprietary technology, they are developing programmable, long-acting mRNA treatments that have the potential to deliver precise and multi-functional therapies, offering potentially curative solutions for various diseases. By programming logic-based circuits into the mRNA, Strand enables the therapeutic protein payload to act only in diseased cells, while turning off in healthy cells, increasing the therapeutic window and improving treatment options for cancer and other life-threatening conditions.
Founded by leading mRNA researchers from the MIT Synthetic Biology Center, Strand has developed the first programming language for mRNA and is building a pipeline of programmable mRNA therapeutics. Their goal is to enable precise control of protein expression, including location, timing, intensity, and duration, to provide highly targeted and potentially curative treatments. With a focus on partnerships and a mission to transform patients' lives, Strand Therapeutics is at the forefront of the future of biology.
Generated from the website